IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies.
Guido LancmanKian ParsaKrzysztof KotlarzLisa AveryAlaina LurieAlex Lieberman-CribbinHearn Jay ChoSamir S ParekhShambavi RichardJoshua RichterCesar RodriguezAdriana RossiLarysa J SanchezSantiago ThibaudSundar JagannathAjai ChariPublished in: Blood cancer discovery (2023)
To the best of our knowledge, this is the first study to comprehensively analyze risk factors and mitigation strategies to prevent infections in myeloma patients receiving anti-BCMA bispecific antibodies. Profound and prolonged hypogammaglobulinemia was universal among responders, while immunoglobulin replacement was associated with 90% lower rates of grade 3-5 infections. See related commentary by Garfall and Stadtmauer .